In preparation for the new year, we've provided a special advance listing of upcoming medicines that we are sure will be helpful to patients around the world.
1. Latanoprostene bunod ophthalmic solution (Vyzulta)
Vyzulta (latanoprostene bunod ophthalmic solution) is a prostaglandin analog approved by the FDA on November 2, 2017, for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. These are the first eyedrops to be approved in a while that reduce eye pressure. The product is intended to be easily applied once-daily.
2. Telotristat ethyl (Xermelo)
Xermelo (telotristat ethyl) is a tryptophan hydroxylase inhibitor indicated for adults with severe diarrhoea associated with a condition called carcinoid syndrome. Carcinoid syndrome is a set of symptoms sometimes seen in people with carcinoid tumours, whose tumours release excess amounts of the hormone serotonin, resulting in diarrhea, flushing of the face and cramps.
Xermelo is used together with other medicines, called somatostatin analogues, when those medicines are not sufficient on their own to control the diarrhoea. Telotristat inhibits enzymes needed for the production of serotonin and by reducing the production of serotonin it relieves the symptoms of the condition. This is the first oral treatment of its type for carcinoid syndrome - a pill that is recommended to be taken three times a day with food.
3. Copanlisib (Aliqopa)
Aliqopa (copanlisib) is a kinase inhibitor approved by the FDA on September 14, 2017, for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies. Follicular lymphoma is the most common slow-growing form of Non-Hodgkin Lymphoma (NHL), accounting for approximately 12% of all B-cell NHLs.
During the clinical trials patients received copanlisib at 60 mg on days 1, 8, and 15, repeated every 28 days and after 16 weeks they were reviewed for their response to the treatment. Most patients saw lesion shrinkage in response to treatment with copanlisib. ''The 59.2% overall response rate included complete responses in 12.0% of patients and partial responses in 47.2% of patients. An additional 29.6% of patients had stable disease, resulting in a disease control rate of 85.9%.''
4. Abemaciclib (Verzenio)
Verzenio (abemaciclib) is a kinase inhibitor approved by the FDA on September 28, 2017 for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer:
- In combination with an endocrine therapy, called fulvestrant, in patients with disease progression following endocrine therapy
- As monotherapy in patients with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting
- The recommended starting doses are 150 mg twice daily in combination with fulvestrant or 200 mg twice daily as monotherapy.
You can find out more about these medicines on our product pages - just type the product name into the search bar.
If you want to know more about the release dates of these medicines - please contact our Support Team.